⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562816 | 0.76 | — | — | |
| SCHEMBL197665 | 0.74 | — | — | |
| SCHEMBL868374 | 0.72 | — | — | |
| SCHEMBL10403 | 0.70 | — | — | |
| SCHEMBL2302823 | 0.70 | — | — | |
| SCHEMBL8823244 | 0.69 | — | — | |
| SCHEMBL15271705 | 0.67 | — | — | |
| SCHEMBL15271903 | 0.67 | — | — | |
| SCHEMBL15271291 | 0.67 | — | — | |
| SCHEMBL18341484 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114174279-B | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | claimed |
| EP-4010317-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-06-19 | — | — | EP | claimed |
| CN-118019736-A | Molecular gel compound designed based on cereblon protein and application thereof | 标新生物医药科技(上海)有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | claimed |
| US-20240083886-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2024-03-14 | — | — | US | claimed |
| WO-2024051766-A1 | MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-03-14 | — | — | WO | claimed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | claimed |
| EP-4100408-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-28 | — | — | EP | claimed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | claimed |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | claimed |
| WO-2016115272-A1 | BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2016-07-21 | — | — | WO | claimed |
| EP-3033341-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-06-22 | — | — | EP | claimed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | claimed |
| EP-2909204-A1 | GSK3 INHIBITORS AND METHODS OF USE THEREOF | The Broad Institute, Inc. (US) | 2015-08-26 | — | — | EP | claimed |
| WO-2015022263-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | claimed |
| WO-2014059383-A1 | GSK3 INHIBITORS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. (US) | 2014-04-17 | — | — | WO | claimed |
| JP-4792126-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | claimed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | claimed |